JPWO2020180865A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020180865A5
JPWO2020180865A5 JP2021552522A JP2021552522A JPWO2020180865A5 JP WO2020180865 A5 JPWO2020180865 A5 JP WO2020180865A5 JP 2021552522 A JP2021552522 A JP 2021552522A JP 2021552522 A JP2021552522 A JP 2021552522A JP WO2020180865 A5 JPWO2020180865 A5 JP WO2020180865A5
Authority
JP
Japan
Prior art keywords
composition
administration
formulated
subject
hsp60
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524325A5 (https=
JP2022524325A (ja
JP7738377B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020794 external-priority patent/WO2020180865A1/en
Publication of JP2022524325A publication Critical patent/JP2022524325A/ja
Publication of JP2022524325A5 publication Critical patent/JP2022524325A5/ja
Publication of JPWO2020180865A5 publication Critical patent/JPWO2020180865A5/ja
Priority to JP2025017178A priority Critical patent/JP2025087689A/ja
Application granted granted Critical
Publication of JP7738377B2 publication Critical patent/JP7738377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552522A 2019-03-04 2020-03-03 神経炎症の調節 Active JP7738377B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017178A JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813556P 2019-03-04 2019-03-04
US62/813,556 2019-03-04
PCT/US2020/020794 WO2020180865A1 (en) 2019-03-04 2020-03-03 Modulating neuroinflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017178A Division JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Publications (4)

Publication Number Publication Date
JP2022524325A JP2022524325A (ja) 2022-05-02
JP2022524325A5 JP2022524325A5 (https=) 2023-03-10
JPWO2020180865A5 true JPWO2020180865A5 (https=) 2023-03-10
JP7738377B2 JP7738377B2 (ja) 2025-09-12

Family

ID=72337602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552522A Active JP7738377B2 (ja) 2019-03-04 2020-03-03 神経炎症の調節
JP2025017178A Pending JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017178A Pending JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Country Status (7)

Country Link
US (1) US20220143139A1 (https=)
EP (1) EP3934674A4 (https=)
JP (2) JP7738377B2 (https=)
KR (1) KR20210148163A (https=)
CN (1) CN113795266A (https=)
CA (1) CA3132333A1 (https=)
WO (1) WO2020180865A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
KR102829678B1 (ko) * 2021-12-13 2025-07-04 차의과학대학교 산학협력단 신경전구세포를 포함하는 시신경병증의 예방 또는 치료용 약학 조성물
WO2024220474A1 (en) * 2023-04-21 2024-10-24 The Schepens Eye Research Institute, Inc. Methods of treating age-related macular degeneration targeting igfbpl-1
AU2024308069A1 (en) * 2023-06-27 2026-02-05 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
JP2013529292A (ja) 2010-04-13 2013-07-18 エム−ラブ・アクチェンゲゼルシャフト 緑内障の診断方法
US10842849B2 (en) * 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy

Similar Documents

Publication Publication Date Title
CA2784492C (en) Non-irritating ophthalmic povidone-iodine compositions
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
JP2022506111A5 (https=)
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
JP7299889B2 (ja) 緑内障を治療するためのＷｎｔ５ａの調節
RU2010117178A (ru) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
AU2016326750B2 (en) Viral conjunctivitis treatment using ranpirnase and/or amphinase
JP2009544734A5 (https=)
CN110678193A (zh) 治疗和神经保护肽
JPWO2020180865A5 (https=)
JPWO2020092019A5 (https=)
JP2015514760A5 (https=)
JP2022528566A5 (https=)
US8318739B2 (en) Remedy for corneal diseases
JP2018534274A (ja) 一過性受容体電位カチオンチャネルサブファミリーｍメンバー８（ｔｒｐｍ８）拮抗薬及び使用方法
Neroev et al. The impact of corticosteroid therapy on the bacterial corneal ulcer healing process
Wang et al. Intravitreal injection of triamcinolone acetonide for macular edema due to retinitis pigmentosa and other retinal diseases
HK40104751A (zh) 治疗青光眼的wnt5a的调节
JPWO2020200241A5 (https=)
Edwards Acute Bacterial Tenonitis and Conjunctivitis following Intravitreal Injection
Zhang et al. The effect of fingomolid (FTY720) protecting the retina of rats from light-induced retinal degeneration (LIRD)
WO2023215407A3 (en) Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases
AU2015252097A1 (en) Non-irritating ophthalmic povidone-iodine compositions
Yordanov et al. Quality of life in patients with primary open-angle glaucoma depending on the conducted treatment
Maggs What ophtho drugs should I have in my pharmacy?(And what's the dose?).